Literature DB >> 12297128

Effect of fucoidan on fibroblast growth factor-2-induced angiogenesis in vitro.

Sabine Matou1, Dominique Helley, Delphine Chabut, Andrée Bros, Anne-Marie Fischer.   

Abstract

Fucoidans are sulfated polysaccharides extracted from brown marine algae. A purified fucoidan fraction exhibits the same venous antithrombotic activity as heparin in rabbits, but with a lower anticoagulant effect. Because of its heparin-like structure, we postulated that fucoidan might modulate heparin-binding angiogenic growth factor activity. We thus studied its effect, at antithrombotic concentrations, on fibroblast growth factor (FGF)-2-induced proliferation and differentiation of human umbilical vein endothelial cells. The fucoidan effect on endothelial cell differentiation was evaluated by studying the expression of surface proteins (i.e. integrin, adhesion molecule) known to be modulated by FGF-2 and involved in angiogenesis, and by quantifying closed areas delimited by vascular tubes formed on reconstituted basement membrane. Fucoidan had no modulatory effect on the mitogenic activity of FGF-2, but significantly increased tubular structure density induced by FGF-2. Fucoidan alone increased alpha(6) integrin subunit expression with only partially organized tubular structure. In the presence of FGF-2, fucoidan enhanced alpha(6), beta(1) and PECAM-1 and inhibited alpha(v)beta(3) integrin expression. Heparin had no effect in these systems. The most striking effect of fucoidan was observed on alpha(6) expression and tube formation was abolished by monoclonal anti-alpha(6) antibodies. Fucoidan plus FGF-2 effect on alpha(6) expression was markedly decreased by monoclonal anti-FGF-2 antibodies, indicating that fucoidan acts mainly via FGF-2. These results show that, at antithrombotic concentrations, contrary to heparin, fucoidan can enhance vascular tube formation induced by FGF-2 with a modulation of the expression of surface proteins (mainly alpha(6)) involved in angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297128     DOI: 10.1016/s0049-3848(02)00136-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  15 in total

Review 1.  Marine pharmacology in 2001--2002: marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Mark T Hamann
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2005 Mar-Apr       Impact factor: 3.228

2.  Fucoidan functionalization on poly(vinyl alcohol) hydrogels for improved endothelialization and hemocompatibility.

Authors:  Yuan Yao; Aung Moe Zaw; Deirdre E J Anderson; Monica T Hinds; Evelyn K F Yim
Journal:  Biomaterials       Date:  2020-04-01       Impact factor: 12.479

Review 3.  Angiosuppressive properties of marine-derived compounds-a mini review.

Authors:  Patrick Y K Yue; H M Leung; Adela J Li; Tracy N C Chan; T S Lum; Y L Chung; Y H Sung; M H Wong; Kelvin S Y Leung; Eddy Y Zeng
Journal:  Environ Sci Pollut Res Int       Date:  2015-10-31       Impact factor: 4.223

4.  Anticancer drugs from marine flora: an overview.

Authors:  N Sithranga Boopathy; K Kathiresan
Journal:  J Oncol       Date:  2011-02-27       Impact factor: 4.375

Review 5.  Marine polysaccharides: a source of bioactive molecules for cell therapy and tissue engineering.

Authors:  Karim Senni; Jessica Pereira; Farida Gueniche; Christine Delbarre-Ladrat; Corinne Sinquin; Jacqueline Ratiskol; Gaston Godeau; Anne-Marie Fischer; Dominique Helley; Sylvia Colliec-Jouault
Journal:  Mar Drugs       Date:  2011-09-23       Impact factor: 6.085

Review 6.  Marine polysaccharides from algae with potential biomedical applications.

Authors:  Maria Filomena de Jesus Raposo; Alcina Maria Bernardo de Morais; Rui Manuel Santos Costa de Morais
Journal:  Mar Drugs       Date:  2015-05-15       Impact factor: 5.118

Review 7.  Fucoidans in Nanomedicine.

Authors:  Lucas Chollet; Pierre Saboural; Cédric Chauvierre; Jean-Noël Villemin; Didier Letourneur; Frédéric Chaubet
Journal:  Mar Drugs       Date:  2016-07-29       Impact factor: 5.118

8.  Identification of a Pro-Angiogenic Potential and Cellular Uptake Mechanism of a LMW Highly Sulfated Fraction of Fucoidan from Ascophyllum nodosum.

Authors:  Nicolas Marinval; Pierre Saboural; Oualid Haddad; Murielle Maire; Kevin Bassand; Frederic Geinguenaud; Nadia Djaker; Khadija Ben Akrout; Marc Lamy de la Chapelle; Romain Robert; Olivier Oudar; Erwan Guyot; Christelle Laguillier-Morizot; Angela Sutton; Cedric Chauvierre; Frederic Chaubet; Nathalie Charnaux; Hanna Hlawaty
Journal:  Mar Drugs       Date:  2016-10-17       Impact factor: 5.118

9.  Promoting Wound Healing Using Low Molecular Weight Fucoidan in a Full-Thickness Dermal Excision Rat Model.

Authors:  Jun-Hyeong Park; Seong-Hun Choi; Soo-Jin Park; Young Joon Lee; Jong Hyun Park; Phil Hyun Song; Chang-Mo Cho; Sae-Kwang Ku; Chang-Hyun Song
Journal:  Mar Drugs       Date:  2017-04-07       Impact factor: 5.118

10.  Fucoidan reduces secretion and expression of vascular endothelial growth factor in the retinal pigment epithelium and reduces angiogenesis in vitro.

Authors:  Michaela Dithmer; Sabine Fuchs; Yang Shi; Harald Schmidt; Elisabeth Richert; Johann Roider; Alexa Klettner
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.